Bristol-Myers Squibb Co. shocked the market late last week when it announced a Phase III trial exploring its market leading PD-1 inhibitor Opdivo (nivolumab) as a first-line treatment for NSCLC had missed its primary endpoint. However, Datamonitor Healthcare analyst Dustin Phan told Scrip Opdivo will still pose a barrier to market entry for many late-phase pipeline therapies because of its strong uptake as a second-line treatment.
Topline data from the pivotal Phase III CheckMate 026 trial revealed that Opdivo failed to meet its primary endpoint of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?